Prostatic Arterial Embolization Benign Prostate Hyperplasia Lower Urinary Tract Symptoms Meta-Analysis

5-alpha Reductase Inhibitors/*adverse effects Drug Therapy Combination Ejaculation/drug effects Erectile Dysfunction/*chemically induced/drug therapy Finasteride Humans Libido/*drug effects Male Middle Aged Prostatic Hyperplasia/*drug therapy Randomized Controlled Trials as Topic *5α-Reductase Inhibitors *Erectile Dysfunction *Meta-Analysis *Sexual Dysfunction

Transurethral enucleation of the prostate transvesical open prostatectomy benign prostatic hyperplasia meta-analysis

Aged Humans Male Middle Aged Prostatic Hyperplasia/blood Prostatic Neoplasms/*blood Publication Bias Sensitivity and Specificity Zinc/*blood

Humans Laser Therapy Male Prostate/radiation effects Prostatic Hyperplasia *Randomized Controlled Trials as Topic Transurethral Resection of Prostate Volatilization Benign prostate hyperplasia (BPH) Meta-analysis Photoselective vaporization of the prostate (PVP) Transurethral resection of the prostate (TURP)

非肌层浸润性膀胱癌 复发因素 Meta分析 地域差异

Male Humans *Stomach Neoplasms/genetics *Urinary Bladder Neoplasms/genetics Urinary Bladder Membrane Proteins RNA Messenger Antigens Neoplasm/genetics Neoplasm Proteins GPI-Linked Proteins/genetics Psca cancer risk polymorphism rs2294008 (C/T)

Humans *Urinary Diversion/adverse effects *Ureter/surgery Cystectomy/methods Anastomosis Surgical/adverse effects *Vesico-Ureteral Reflux/etiology *Urinary Bladder Neoplasms/surgery Ileum/surgery *Pyelonephritis/complications Bladder Orthotopic ileal neobladder Radical cystectomy Tumor Ureteroenteric anastomosis Urinary diversion

detrusor muscle en bloc resection of bladder tumor non-muscle invasive bladder cancer

Humans *Urinary Bladder/pathology Cystectomy/methods Prognosis Prospective Studies Neoplasm Recurrence Local/pathology *Urinary Bladder Neoplasms/pathology Biomarkers biomarker neutrophil-to-lymphocyte ratio prognostic factor radical cystectomy recurrence urothelial carcinoma

肌层浸润性膀胱癌 根治性膀胱切除术 综合治疗 疗效评价

Blood Transfusion/*mortality Combined Modality Therapy Cystectomy/*mortality Humans *Perioperative Care Prognosis Survival Rate Urinary Bladder Neoplasms/pathology/*therapy Bladder cancer Blood transfusion Cystectomy Meta-analysis Oncology Systematic review

Diet Fruit Humans Male Prospective Studies Risk Risk Factors *Urinary Bladder Neoplasms/epidemiology/etiology *Vegetables

*Bipolar Disorder Cystectomy Humans *Urinary Bladder Neoplasms/surgery Urologic Surgical Procedures

Bayes Theorem Cystectomy Humans *Laparoscopy Postoperative Complications/surgery *Robotic Surgical Procedures *Robotics Treatment Outcome *Urinary Bladder Neoplasms/surgery

膀胱肿瘤 磁共振成像 膀胱影像报告和数据系统 肌层浸润 Meta分析

Cystectomy/methods Humans Quality of Life *Urinary Bladder Neoplasms/surgery *Urinary Diversion/methods *Urinary Reservoirs Continent nursing systematic review urinary diversion

Antibodies Monoclonal Humanized/*therapeutic use *Carcinoma Transitional Cell/drug therapy Humans Prognosis Retrospective Studies *Urinary Bladder Neoplasms/drug therapy Metastatic urothelial carcinoma Pembrolizumab Prognostic factor Janssen and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas Bayer Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Consulting or Advisory Role: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Speakers Bureau: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen Movember Foundation. The other authors declare no conflicts of interest associated with this manuscript.

Catheterization time Conventional transurethral resection Cáncer vesical primario no músculo-infltrante Duración de la estancia hospitalaria En-bloc transurethral resection Length of hospital stay Primary non-muscle invasive bladder cancer Recurrence Recurrencia Resección transuretral convencional Resección transuretral en bloque Tiempo de sondaje

Area Under Curve Female Humans Male Neoplasm Recurrence Local/diagnosis Prospective Studies Recurrence Sensitivity and Specificity *Urinary Bladder Neoplasms/diagnosis Biomarker Bladder cancer Diagnostic accuracy Systematic review Xpert